Skip to content

Ventilatory burden and blood pressure response to CPAP: A secondary analysis of the APPLES trial.

Sep 2026 · Sleep Medicine · Vol 149, pp. 109296 · 0 citations · 31 references
Medicine

Abstract

Background

Continuous Positive Airway Pressure (CPAP) is the standard treatment of obstructive sleep apnea (OSA), but has a heterogeneous blood pressure (BP) lowering effect. We hypothesized that Ventilatory Burden (VB), a metric better reflecting the entire burden of pathological airflow, may predict CPAP-induced BP reduction.

Methods

We conducted a secondary analysis of the Apnea Positive Pressure Long-term Efficacy Study (APPLES) cohort. Participants were stratified by baseline VB (>20% breaths with < 50% amplitude) and OSA severity (AHI ≥ 30). Linear regression models were used to assess the relationship between these subgroups, CPAP adherence, and morning/evening BP changes at 2 and 6 months. The subgroup analyses were exploratory, and reported p values were nominal.

Results

A total of 962 participants were initially enrolled with complete baseline assessments, of whom 749 completed the 2-month follow-up and 649 completed the 6-month follow-up. At 2 months, active CPAP was associated with a reduction in morning SBP relative to sham CPAP among participants with High VB and good adherence (β = 1.73 mmHg, p = 0.037). This association was not observed at 6 months. In the OSA severity-stratified analysis, active CPAP was associated with morning SBP reduction in the non-severe OSA subgroup with good adherence at both follow-ups.

Conclusion

Among participants with High VB and good CPAP adherence, active CPAP was associated with an early reduction in morning SBP relative to sham CPAP. This association was observed at 2 months but not at 6 months. Prospective studies incorporating prespecified treatment-interaction analyses are required to determine whether VB can identify blood pressure responders to CPAP.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.